The Medicines Company’s worth declared at $9.7bn post Novartis’ buyout
Category: #health  By Nikita Chaurasia  Date: 2019-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

The Medicines Company’s worth declared at $9.7bn post Novartis’ buyout


Novartis has reportedly planned the purchase with a target of adding inclisiran, a potential cholesterol lowering drug of The Medicines Company to its existing cardiovascular portfolio

Swiss multinational pharmaceutical company, Novartis International AG recently announced plans to acquire a US-based biopharmaceutical firm, The Medicines Company for a transaction of USD $85 per share in cash.  The acquisition, the Medicines Company’s fully diluted equity value is likely to be worth approximately USD $9.7 billion, which marks a premium of almost 45% to the company’s closing share price.

The strategic acquisition of The Medicines Company will aid Novartis to continue building its pipeline strength in a key therapeutic area. The move will also add inclisiran, a first-in-class small interfering RNA (siRNA) inhibitor targeting PCSK9 with the potential to fundamentally change the treatment of elevated low-density lipoprotein cholesterol (LDL-C) in high-risk patients.

The US-based Company reportedly announced data from its clinical program consisting of 3 Phase III trials for inclisiran, involving over 3,600 high-risk patients with atherosclerotic cardiovascular disease and familial hypercholesterolemia. The drug demonstrated potent & durable LDL-C reduction in all the trials, with high safety and tolerability profile.

Medicines Company has plans to file regulatory submissions for inclisiran in the U.S. by the end of 2019 & in Europe in early 2020. Furthermore, ORION-4, an ongoing clinical trial is investigating the cardiovascular morbidity & mortality advantages of inclisiran in 15000 patients for a period of 5 years.

Marie-France Tschudin, President, Novartis Pharmaceuticals was reportedly quoted saying that the company Novartis has a longstanding history of delivering transformational cardiovascular treatments for patients. The company is elated by this opportunity to add inclisiran to its cardiovascular portfolio.

The new investigational medicine has the potential to specifically address one of the largest areas of underserved patient requirements. Tschudin added that the firm believes that its strong capabilities & global footprint can aid worldwide access to this much-needed treatment.

With the expansion of its cardiovascular portfolio, Novartis would be enabled to leverage its core commercial capabilities as well as its strong cardiovascular field force both in the U.S. and globally.
 

Source Credit: https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Sims Recycling confirms ISO 27001 certification for Noida facility
Sims Recycling confirms ISO 27001 certification for Noida facility
By Nikita Chaurasia

SRS clients will be assured about the secure management of their IT and electronic assets by the information security management standard Sims Recycling Solutions (SRS), provider of IT asset disposition (ITAD) and electronics recycling, was recently...

NTT Data Services inks a definitive agreement to acquire Flux7
NTT Data Services inks a definitive agreement to acquire Flux7
By Nikita Chaurasia

NTT Data Services, a U.S.-based IT service provider, has reportedly inked a definitive agreement to acquire AWS premier consulting partner, Flux7 to accelerate and expand the company’s capabilities to bring IT workloads to the cloud.  Acc...

CloudCheckr unveils a new Business Partner Program at AWS re
CloudCheckr unveils a new Business Partner Program at AWS re
By Nikita Chaurasia

CloudCheckr, a renowned New York based cloud management solution company, has reportedly revealed a world-class partner enablement program at the AWS (Amazon Web Services) re. The new program enables IaaS and cloud service sellers to build a profitab...